Non-Hodgkin lymphoma

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023
Oncology, Health, Infectious Diseases, Genetics, General Health, Clinical Trials, Biotechnology, ASCO, NHP, Cell, OTC, Novartis, Research, Patient, Gene editing, Agriculture, HBV, Hepatocyte, Information technology, Trial of the century, Development, Cash, IND, Hemoglobinopathy, Precision BioSciences, Lilly, Non-Hodgkin lymphoma, HBsAg, DMD, Duchenne muscular dystrophy, State Administrative Expenses, Molecular Partners, Cyclophosphamide, ASH, Insurance, CTA, NHL, Tissue, University, FDA, R, Precision, Drug discovery, CMC, Administration, Infant, CAR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PCSK9, Food, Vivo, Sickle cell disease, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.
  • Responses from the FDA on analytical methods, proposed potency assays, and manufacturing processes are further guiding clinical development.
  • The Company also plans to complete Phase 1 dose escalation for PBCAR19B in the earlier line NHL setting.
  • Fiscal Year 2022 Financial Results:
    Cash and Cash Equivalents: As of December 31, 2022, Precision had $189.6 million in cash and cash equivalents.

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

Retrieved on: 
Friday, February 24, 2023
Safety, Therapy, Cancer, Non-Hodgkin lymphoma, Toxic leukoencephalopathy, Trial of the century, Interleukin 12, Neoplasm, Tumor microenvironment, Immunity, Cytokine, Werewolf, Lymphoma, Pharmaceutical industry, Vaccine, Patient

WATERTOWN, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330, the Company’s lead INDUKINETM molecule targeting Interleukin-12 (IL-12). The Phase 1 clinical trial is a first-in-human, multi-center, open-label trial that will evaluate WTX-330 in patients with advanced or metastatic solid tumors or lymphoma resistant to checkpoint inhibitors or for which checkpoint inhibitors are not approved.

Key Points: 
  • “Dosing the first patient in our Phase 1 trial of WTX-330 marks the second INDUKINE molecule arising from our PREDATORTM protein engineering platform to enter the clinic.
  • Our continued transition into a clinical stage company comes at an exciting time for Werewolf following the initiation of a Phase 1/1b clinical study of WTX-124 last year,” said Daniel J. Hicklin, Ph.D., Werewolf’s Founder and Chief Executive Officer.
  • In preclinical studies, WTX-330 exhibited excellent anti-tumor activity and a favorable pharmacokinetic and tolerability profile.
  • For additional information about the trial, please visit www.clinicaltrials.gov using the Identifier: NCT05678998

Global Non-Hodgkin Lymphoma Therapeutics Market to Grow by $5.42 Billion During 2023-2027: - ResearchAndMarkets.com

Retrieved on: 
Friday, February 24, 2023
Pharmaceutical, Health, Oncology, Baxter International, Merck Group, Non-Hodgkin lymphoma, Cancer, Novartis, Eastman Kodak Co. v. Image Technical Services, Inc., Pfizer, Research, Gilead Sciences, AstraZeneca, BeiGene, Therapy, Biogen, GSK plc, Bayer, Bristol-Myers Squibb Co. v. Superior Court, Eli Lilly and Company, Lymphoma, Pharmaceutical industry

This study identifies the research grants and funding as one of the prime reasons driving the non-Hodgkin lymphoma therapeutics market growth during the next few years.

Key Points: 
  • This study identifies the research grants and funding as one of the prime reasons driving the non-Hodgkin lymphoma therapeutics market growth during the next few years.
  • Also, growing awareness about cancer and increase in patient assistance programs and reimbursements will lead to sizable demand in the market.
  • The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
  • The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Data Presented on Gamida Cell’s Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Saturday, February 18, 2023
Research, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Toxicity, Therapy, Hope, University of Minnesota Medical School, CD62L, CD56, TCT, Safety, Phenotype, NK, Patient, Tandem, CD16, LAG3, Cell, Center for International Blood and Marrow Transplant Research, University, Lymph, Bone marrow, Integrin alpha-1, Knowledge, Society, Transplant, CD57, LAMP1, Spatial analysis, Non-Hodgkin lymphoma, Pharmaceutical industry, Medical imaging

The meetings took place February 15-19 virtually and in person in Orlando, Florida.

Key Points: 
  • The meetings took place February 15-19 virtually and in person in Orlando, Florida.
  • “The data presented at Tandem demonstrate Gamida Cell’s expertise in developing potent, potentially curative cell therapies for patients with hematologic malignancies,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.
  • “The translational data from our Phase 3 study of omidubicel, our lead product candidate, show faster, multi-faceted immune response – as quickly as seven days—in omidubicel-treated patients compared to standard cord blood.
  • Patients transplanted with standard cord blood showed no such correlations at Day 7 post-transplant, and only began to show correlations starting at 14 days post-transplant.

JAYPIRCA™ (pirtobrutinib) Now Available from Onco360 for the Treatment of Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) after at least Two Lines of Systemic Therapy, Including a BTK Inhibitor

Retrieved on: 
Wednesday, February 1, 2023
Pharmaceutical, Health, Oncology, MCL, NHL, Fatigue, Lymphoma, Edema, Diarrhea, Treatment, National Cancer Institute, Non-Hodgkin lymphoma, Pneumonia, Specialty pharmacy, Mantle cell lymphoma, Patient, SEER, United, Eli Lilly, ORR, NCCN, Disease, Partnership, FDA, National Comprehensive Cancer Network, DSM-IV codes, Death, Periodic breathing, Pharmaceutical industry, Epidemiology

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Key Points: 
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • “Onco360 is excited to announce our partnership with Eli Lilly and become a specialty pharmacy provider for JAYPIRCA patients,” said Benito Fernandez, Chief Commercial Officer, Onco360.
  • The five-year overall survival (OS) for MCL ranges from 50-70% dependent upon stage of disease.2
    JAYPIRCA, a non-covalent BTKi, is commercialized by Eli Lilly.
  • The most common adverse reactions (> 15%) in patients with MCL are fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.3

Oncology Conference Coverage Service | DelveInsight

Retrieved on: 
Tuesday, February 14, 2023
ASTRO, Biomarker, NHL, Happening, CAR, Immunotherapy, Strategic planning, Investment, Non-Hodgkin lymphoma, ASH, Oncology, Consultant, Patient, Incidence, Lung cancer, Clinical trial, Database, Research, Tumors of the hematopoietic and lymphoid tissues, SWOT, Congress, Intelligence, CRPC, SITC, Connect, Targeted therapy, Growth, AACR, Calendar, ESMO, SOHO, Drug discovery, Quality of life, Conference, NSCLC, LAS, Cancer, B cell, ASCO, Medical imaging, Pharmaceutical industry, Nursing, Prostate, Breast

LAS VEGAS, Feb. 14, 2023 /PRNewswire/ -- DelveInsight, a leading healthcare competitive intelligence and consulting solutions company, released its new case study on Oncology Conference Coverage. A renowned Midcap pharma company with an extensive portfolio in the oncology domain, focussing on major solid tumors in Lung (NSCLC only), Breast (HR+/HER2- and HER2+), Ovarian (Low and High Grade Serous Ovarian carcinoma), and Prostate (CRPC only), whereas under Hematological malignancies, the primary focus was in Non-Hodgkin Lymphoma (B-cell NHL mainly).

Key Points: 
  • A case study on how a leading midcap oncology-focused company utilized DelveInsight's Conference Coverage Service to get real-time and exhaustive insights.
  • The information revolved around next-generation therapies and upcoming biomarkers, wherein DelveInsight provided a detailed analysis of conference coverage outcomes, leading to effective competitive intelligence assessment and anticipation of market trends to develop future road maps
    LAS VEGAS, Feb. 14, 2023 /PRNewswire/ -- DelveInsight, a leading healthcare competitive intelligence and consulting solutions company, released its new case study on Oncology Conference Coverage .
  • DelveInsight's Pharma Conference Coverage Service : A comprehensive offering that provides clients with in-depth coverage of healthcare conferences, events, and trade shows.
  • The conference coverage service includes pre-conference briefings, on-site coverage, post-conference analysis, and custom reporting.

Oncology Conference Coverage Service | DelveInsight

Retrieved on: 
Tuesday, February 14, 2023
ASTRO, Biomarker, NHL, Happening, CAR, Immunotherapy, Strategic planning, Investment, Non-Hodgkin lymphoma, ASH, Oncology, Consultant, Patient, Incidence, Lung cancer, Clinical trial, Database, Research, Tumors of the hematopoietic and lymphoid tissues, SWOT, Congress, Intelligence, CRPC, SITC, Connect, Targeted therapy, Growth, AACR, Calendar, ESMO, SOHO, Drug discovery, Quality of life, Conference, NSCLC, LAS, Cancer, B cell, ASCO, Medical imaging, Pharmaceutical industry, Nursing, Prostate, Breast

LAS VEGAS, Feb. 14, 2023 /PRNewswire/ -- DelveInsight, a leading healthcare competitive intelligence and consulting solutions company, released its new case study on Oncology Conference Coverage. A renowned Midcap pharma company with an extensive portfolio in the oncology domain, focussing on major solid tumors in Lung (NSCLC only), Breast (HR+/HER2- and HER2+), Ovarian (Low and High Grade Serous Ovarian carcinoma), and Prostate (CRPC only), whereas under Hematological malignancies, the primary focus was in Non-Hodgkin Lymphoma (B-cell NHL mainly).

Key Points: 
  • A case study on how a leading midcap oncology-focused company utilized DelveInsight's Conference Coverage Service to get real-time and exhaustive insights.
  • The information revolved around next-generation therapies and upcoming biomarkers, wherein DelveInsight provided a detailed analysis of conference coverage outcomes, leading to effective competitive intelligence assessment and anticipation of market trends to develop future road maps
    LAS VEGAS, Feb. 14, 2023 /PRNewswire/ -- DelveInsight, a leading healthcare competitive intelligence and consulting solutions company, released its new case study on Oncology Conference Coverage .
  • DelveInsight's Pharma Conference Coverage Service : A comprehensive offering that provides clients with in-depth coverage of healthcare conferences, events, and trade shows.
  • The conference coverage service includes pre-conference briefings, on-site coverage, post-conference analysis, and custom reporting.

Araris Biotech AG to Present at the 22nd Annual PepTalk: Protein Science and Production Week

Retrieved on: 
Thursday, January 19, 2023
Non-Hodgkin lymphoma, Control, Monoclonal antibody, Combination, Production, Safety, Efficacy, ADC, Therapeutic index, Mouse, NHL, RATS, Fine chemical, Pharmaceutical industry, Vaccine, Lymphoma

ZURICH, Switzerland, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Bernd Schlereth, Ph.D., chief development officer, will deliver an oral presentation at the 22nd annual PepTalk: Protein Science and Production Week being held January 16- 20, 2023 in San Diego.

Key Points: 
  • ZURICH, Switzerland, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Bernd Schlereth, Ph.D., chief development officer, will deliver an oral presentation at the 22nd annual PepTalk: Protein Science and Production Week being held January 16- 20, 2023 in San Diego.
  • Single dose treatment of ARC-02 induced effective and long-lasting tumor responses at 3-4x lower payload dose compared to Polivy® in NHL tumor models.
  • In vivo pharmacokinetic studies in mice, rats and monkeys demonstrated an antibody-like exposure profile of the ADC with no premature toxin loss in circulation.
  • In repeat-dose cynomolgus monkey toxicity studies, ARC-02 showed a highest non-severely toxic dose (HNSTD) of 24mg/kg which is 8x higher than Polivy®.

Global Glycosylated Hemoglobin And C Peptide Market 2022 - 2028: Increasing Prevalence of Diabetes Across the Globe and Growing Geriatric Population Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 19, 2023
Diabetes, Pharmaceutical, Health, Medtronic, Non-Hodgkin lymphoma, Anemia, Millet, WHO, Capsule, Degenerative disease, International, International Crops Research Institute for the Semi-Arid Tropics, Pregnancy, Partnership, C-peptide, Hematologic disease, Patient, Prevalence, Genentech, Research, Pfizer, Policy, Fine chemical, Pharmaceutical industry

The global glycosylated hemoglobin and c peptide market is anticipated to grow at a considerable CAGR during the forecast period.

Key Points: 
  • The global glycosylated hemoglobin and c peptide market is anticipated to grow at a considerable CAGR during the forecast period.
  • The market is expected to grow with some emerging trends which includes increasing prevalence of diabetes across the globe and growing geriatric population, growing advancements in pharmaceutical and biopharmaceutical sectors and on-going research on C-peptide and glycosylated hemoglobin.
  • The global glycosylated hemoglobin and c peptide market is segmented based on product and application.
  • The Asia-Pacific is going to be a good market for glycosylated hemoglobin and c peptide during the forecasted period.

Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Multiple sclerosis, Disease, Seizure, News, Castleman disease, Infection, Associate, Hospital, Non-Hodgkin lymphoma, Blood, GlaxoSmithKline Pharmaceuticals Ltd, ODT, University, Person, Lymphoma, RRMS, Liver injury, MS, Posterior reversible encephalopathy syndrome, Headache, QT interval, Melanoma, Status epilepticus, Safety, Blood pressure, Macular edema, Squamous cell carcinoma, FDA, MD, Risk, Angioedema, Sinusitis, Pediatrics, Hives, Vaccine, Bradycardia, Rash, Tongue, Children's Hospital Los Angeles, AV, Water, Patient, History, Medicine, Neurology, Abdominal pain, Stroke, Back pain, Arrhythmia, MRI, Hypersensitivity, Myocardial infarction, Cough, Incidence, Diarrhea, Pain, Excipient, Food, Generic drug, Pharmaceutical industry, Health insurance, Medical device, Fingolimod, Cycle

To find out more about TASCENSO ODT and Cycle Vita please visit www.tascenso.com and www.cyclevita.life respectively.

Key Points: 
  • To find out more about TASCENSO ODT and Cycle Vita please visit www.tascenso.com and www.cyclevita.life respectively.
  • Due to a risk for bradyarrhythmia and AV blocks patients should be monitored during TASCENSO ODT treatment initiation.
  • Use of live attenuated vaccines during, and for 2 months after stopping TASCENSO ODT, should be avoided.
  • To report SUSPECTED ADVERSE REACTIONS, contact Cycle Pharmaceuticals Ltd at 1-888-533-1625 or the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch .